The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.
Also called NCT06236022
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 276 participants
- Registry
-
NCT06236022
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06236022. Randomized; no masking; primary purpose treatment. Start 2024-01-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
- Acronym
- SDCMK
- Condition
- Dilated Cardiomyopathy
- Condition
- Kaposi's Sarcoma-Associated Herpesvirus Infection
- Intervention (Drug)
- Sirolimus
- Lead sponsor
- Tongji Hospital
- Collaborator
- Wuhan Central Hospital
- Collaborator
- Wuhan Fourth Hospital
- Collaborator
- Wuhan University
Record details
- Record id
cardio:ct-nct06236022- Content hash
0bb226ea786b5a3d217d1df9d1136055be27033cf43d4bdf7d8a013f2364db22